期刊文献+

2011~2013年安阳市疑似预防接种异常反应监测 被引量:5

Surveillance an Suspected Adverse Events Following Immunization,Anyang City,2011-2013
原文传递
导出
摘要 目的分析安阳市疑似预防接种异常反应(AEFI)的发生特征,评价AEFI监测系统运转状况。方法通过AEFI监测系统,收集全市2011~2013年报告的AEFI个案数据,采用描述性方法,对相关指标进行流行病学分析。结果 2011~2013年AEFI监测系统共收到个案363例,其中≤1岁占55.56%,男女性别比为1.66∶1,报告疫苗以全国计划免疫(NIP)疫苗为主;一般反应占88.43%,其中78.24%发生在接种后≤1d;异常反应占9.92%,以过敏性皮疹和卡介苗淋巴结炎为主。估算全市NIP疫苗疑似预防接种异常反应报告发生率为4.54/10万。结论全市AEFI系统的监测质量逐年提高。AEFI常发生在小年龄组儿童接种NIP疫苗时,应为监测重点;NIP疫苗不良反应报告发生率均在预期发生范围内。 Objective To analyze the occurrence characteristics of Adverse Event Following Immunization (AEFI) in An- yang city,so as to evaluate the implementation of AEFI surveillance system. Methods Data were collected on AEFI case reported from 2011 to 2013 through the AEFI Information System, to analyze relevant indicators using descriptive epidemiology. Results The AEFI monitoring system received a total of 363 cases from 2011 to 2013,among them, targets aged ≤1 year accounted for 55.56% ,the sex ratio of male and female was 1.66 : 1. NIP vaccine had high incidence of AE- FIs. 88.43% AEFIs were common, among them 78.24 % occurred ≤ 1 after vaccination;abnormal reaction rate of 9.92%, Allergic rash and BCG lymphadenitis mainly. The vaccine reaction estimated reporting rate of NIP vaccines was 4.54/102. Conclusion The quality of AEFI surveillance is raised year by year. AEFIs often occur in young children and NIP vaccines,and they are the focus of the AEFI surveillance. The reported reaction rates of NIP vaccines occur in the expected range.
作者 王德民
出处 《预防医学论坛》 2014年第9期697-700,共4页 Preventive Medicine Tribune
关键词 疑似预防接种异常反应 监测 疫苗 Adverse events following immunization Surveillance Vaccines
  • 相关文献

参考文献6

二级参考文献34

  • 1郭飚,曹雷,曹玲生,徐立君,梁晓峰,张振国,罗耀星,孙印旗,彭国文,赵占杰.河北、广东省预防接种副反应监测试点培训效果评估[J].中国计划免疫,2005,11(4):302-305. 被引量:34
  • 2应永平,王永林,周亚亚.无细胞与全细胞百白破联合疫苗接种副反应调查[J].中国计划免疫,2006,12(1):71-71. 被引量:20
  • 3庄菱,郭飚,刘大卫,曹玲生,曹雷.全国预防接种异常反应监测省级师资培训效果评估[J].中国计划免疫,2006,12(3):218-220. 被引量:9
  • 4WHO/Immunization Vaccines and Biologicals(IVB). Joint Medical Products Assessment Tools of National Regulatory System Vaccines Assessment[S]. Geneva, Switzerland, 2004.
  • 5WHO&WPRO. Immunization safety surveillance:guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization[S]. Manila, Philiodines. 1999.
  • 6[1]WHO.Immunization safety surveillance:guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization[A].In:Western Pacific Regional Office WHO,ed.:World Health Organization,1999.
  • 7[2]Plotkin SA.Lessons learned concerning vaccine safety[J].Vaccine,2002,20:S16-S19.
  • 8[3]Bonhoeffer J,Heininger U.Adverse events following immunization:perception and evidence[J].Paediatric and neonatal infections,2007,20:237-246.
  • 9[4]Duclos P.Aglobal perspective on vaccine safety[J].Vaccine,2004,22:2059-2063.
  • 10[5]Duclos P,Bentsi-Enchill A,Pfeifer D.Vaccine safety and adverse events:lessons learnt[A].In:Kaufmann SHE,Lambert P-H,eds.The grand challenge for the future:vaccines for poverty-related diseases from bench to field.BasehBirkhauser Verlag 2005:21.

共引文献258

同被引文献32

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部